Searched for
CDMOS IN PHARMA
Nifty stuck in a range but small and midcaps are where real money is being made: Ashish ChaturmohtaIndian stock markets may appear stagnant, but opportunities exist in small and midcap stocks. JM Financial's Ashish Chaturmohta highlights ...- Two separate venues for pharma industry expos in Delhi-NCRCPHI India and PMEC India are expanding their pharmaceutical expos to two venues in Delhi-NCR. This move aims to support the rapid growth o...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- War, falling markets, and a two-year window: Why Vikas Khemani is buying banks, aviation, and pharma right nowIndian markets are down, presenting a buying opportunity for long-term investors. Vikas Khemani of Carnelian Asset Management sees potentia...
- Health makes wealth, says Equirus, as healthcare fundraising crosses pre-Covid high of Rs 62,432 croreIndia’s healthcare and life sciences sector has surpassed its Covid-era fundraising peak, with inflows crossing Rs 62,432 crore, says Equir...
- Market rally ahead? Earnings revival, PSU banks & NBFCs in focus, says InCred’s Aditya SoodIndia’s market is entering a new earnings-led cycle, says InCred AM’s Aditya Sood. With Nifty earnings expected to grow 10–12% and midcaps ...
- Hospitals, CDMOs to lead pharma growth; generics face weak FY27, says JM Financial’s Amey ChalkeIndian healthcare is entering a new growth cycle, with hospitals and CDMO players expected to deliver strong 20% EBITDA CAGR, while large g...
- Pharma tariffs and value retailers: Sudip Bandyopadhyay shares market outlookSudip Bandyopadhyay advises caution in pharma due to US tariff uncertainties, recommending domestic-focused companies like Mankind Pharma f...
- Sun Pharma stares at 8-10% profit risk amid 100% Trump tariffs, says HSBC. Can the giant navigate this?Sun Pharma faces potential impact from the US 100% tariff on patented drugs, which could reduce FY26–27 earnings by 8–10%. Generic drugs re...
- Diamond player Shree Ramkrishna Exports forays into pharma businessShree Ramkrishna Exports, a prominent natural diamond company, has ventured into the pharmaceutical industry with the launch of Kriam Pharm...
- Macquarie sees potential upside in Indian pharma and CDMO stocksMacquarie is optimistic about Indian pharma and CDMO companies, predicting significant upside potential due to recent market corrections an...
- China’s India headache: The growing pharmaceutical industryIndian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desir...
- US tariffs will have minimal impact on Indian pharma service companies like CDMOs: ReportExporters can pass on cost increases to consumers, and the favourable USD/INR exchange rate and increased outsourcing opportunities are exp...
- India's CDMO market set to double by 2028 amid Asia's healthcare boomIndia's CDMO market is set to grow from USD 7 billion to USD 14 billion by 2028. This growth is driven by its strong stance in API manufact...
- Pharma stocks catch a cold as US softens stance on Biosecure ActShares of Syngene International dropped 5.7%, Piramal Pharma fell 4.2%, Lauras Labs and Neuland Laboratories declined 3% and Divi's Laborat...
- Strides Pharma's OneSource raises Rs 801 crore in pre-listing roundOneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and W...
- Suven Pharma to acquire controlling stake in Hyderabad-based CDMO Sapala OrganicSuven will initially acquire a 67.5% equity stake of Sapala subject to customary working capital and net debt adjustments, the remaining st...
- Indian drug manufacturers benefit from Big Pharma interest beyond ChinaChina has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low ...
- After a tough year, Piramal Pharma hopes to regain vigour in 2nd halfPiramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...
- Abhishek Basumallick on where to buy next in pharma sector“There is always a possibility of policy driven action in terms of lowering rates or putting a ceiling on rates, etc so that's something th...
Load More
